Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The insulin receptor substrate 3, pseudogene (IRS3P) is a genomic locus classified as a pseudogene, meaning it shares sequence similarity with the insulin receptor substrate 3 (IRS3) gene but does not produce a functional protein product. IRS3P lacks the capability to participate in insulin receptor signaling, carbohydrate or lipid metabolism, or cellular signaling relevant to diabetes or other metabolic diseases[3]. Unlike functional IRS proteins (such as IRS-1, IRS-2, IRS-3, and IRS-4), which act as cytoplasmic adaptor proteins linking the insulin receptor to downstream signaling cascades (notably the PI3K/Akt pathway and MAP kinase pathways)[1][2], IRS3P has no described biological activity, therapeutic targeting, or disease involvement. It is not a valid molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Insulin receptor substrate 3, pseudogene (IRS3P).